A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim After Single Administration in Pediatric Solid Tumor/Lymphoma Patients
Latest Information Update: 08 Oct 2021
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Lymphoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Dong-A ST
- 04 Oct 2021 Results published in the Clinical Pharmacology and Therapeutics
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 13 Jan 2019 Status changed from recruiting to completed.